GOSS Gossamer Bio, Inc.
Healthcare$0.21+4.58%ClosedMarket Cap: $49.3M
As of 2026-05-25
Valuation
P/E (TTM)
—
PEG
—
P/B
-0.30
P/S
0.89
EV/EBITDA
-1.24
DCF Value
$1.19
FCF Yield
-345.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
99.6%
Operating Margin
-321.9%
Net Margin
-324.8%
ROE
174.9%
ROA
-140.0%
ROIC
-243.6%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $17.0M | 98.6% | $-44.9M | $-46.7M | $— | — |
| Q4 null | $13.8M | 100.0% | $-46.0M | $-47.2M | $— | — |
| FY null | $48.5M | 97.9% | $-163.3M | $-170.4M | $— | — |
| Q3 null | $13.3M | 100.0% | $-49.1M | $-48.2M | $— | — |
| Q2 null | $11.5M | 100.0% | $-38.8M | $-38.3M | $— | — |
| Q1 null | $9.9M | 100.0% | $-36.8M | $-36.6M | $— | — |
| Q4 null | $9.4M | 100.0% | $-36.1M | $-33.0M | $— | — |
| FY null | $114.7M | 100.0% | $-59.9M | $-56.5M | $— | — |
| Q3 null | $9.5M | 100.0% | $-33.9M | $-30.8M | $— | — |
| Q2 null | $95.8M | 100.0% | $52.1M | $49.2M | $— | — |
| Q1 null | $0.00 | NaN% | $-42.0M | $-41.9M | $— | — |
| Q4 2023 | $0.00 | NaN% | $-49.0M | $-48.1M | $-0.21 | — |